BioCryst Pharmaceuticals presented real-world evidence at ACAAI 2026 showing that ORLADEYO (berotralstat), an oral prophylactic therapy for hereditary angioedema (HAE), significantly reduces hospitalizations and emergency visits. Two studies demonstrated that patients initiating or switching to ORLADEYO experienced about a 30% decrease in angioedema-related medical visits, with comparable benefits to other therapies. These findings highlight ORLADEYO's clinical and economic advantages for long-term HAE management. Further clinical data on BioCryst's HAE treatments will also be shared at the conference.
BioCryst Pharmaceuticals' new evidence on ORLADEYO's impact on angioedema-related visits offers context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 18:41 WIB: out of 150 priced US health stocks, 93 rose and 49 fell. FLNA gained 7.05% to USD 0.48 with a strong buy interest (87% buy orders), contrasting with MMED which dropped 4.90% to USD 17.00 and had a shorter typical hold time of 19 days compared to FLNA and HRTX at 39 days each.
Boralex Inc. announced the issuance of C$600 million in green bonds, split into two series with maturities in 2031 and 2036, bearing interest rates of 4.503% and 5.173% respectively. This marks Boralex's first green-labelled corporate securities offe...
Investec Bank Plc, acting as an exempt principal trader and advisor to DBAY Advisors Limited, disclosed the sale of 25,000 ordinary shares of Logistics Development Group Plc on November 12, 2026. The shares were sold at a price of 23 per unit. There ...
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed public dealings in the company's ordinary shares on November 12, 2026. The bank purchased 345,456 shares at prices between 282.561 and 283 pence ...
Ondas Holdings increased its 2026 revenue target to at least $550 million and projects $1.1 billion in sales for 2027, driven by strong growth and planned production expansion. The company reported Q3 revenue of $167.49 million, surpassing estimates ...
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
